title: Targeting angiogenesis in the pathological ovary.
abstract: The ovary is a key tissue in the study of physiological neo-vascularisation in the adult and its study has highlighted important molecules involved in the regulation of angiogenesis in vivo. These include vascular endothelial growth factor, delta-like ligand 4, thrombospondin-1, prokineticin-1 and prostaglandin E2. Targeting these molecular pathways has therapeutic potential and their manipulation has an increasing preclinical and clinical role in the management of the pathological ovary. Targeting angiogenic pathways has utility in the promotion of ovarian angiogenesis to improve tissue and follicle survival and function as well as the prevention and management of ovarian hyperstimulation syndrome. There is a theoretical possibility that targeting angiogenesis may improve the function of the polycystic ovary and a real role for targeting angiogenesis in ovarian cancer.
authors.affiliation: MRC Centre for Reproductive Health, The Queen's Medical Research Institute, The University of Edinburgh, 47 Little France Crescent, Edinburgh EH16 4TJ, UK. w.c.duncan@ed.ac.uk
authors.forename: W Colin
authors.initials: WC
authors.lastname: Duncan
authors.forename: Junko
authors.initials: J
authors.lastname: Nio-Kobayashi
mesh_terms: D048868:Adaptor Proteins, Signal Transducing; D000634:Aminoquinolines / Q000494:pharmacology; D002135:Calcium-Binding Proteins; D006063:Chorionic Gonadotropin / Q000494:pharmacology; D003338:Corpus Luteum / Q000098:blood supply* / Q000187:drug effects; D015232:Dinoprostone / Q000494:pharmacology; D016503:Drug Delivery Systems / Q000379:methods; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000378:metabolism; D007986:Luteinizing Hormone / Q000378:metabolism; D008954:Models, Biological; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D010049:Ovarian Diseases / Q000188:drug therapy / Q000503:physiopathology*; D010051:Ovarian Neoplasms / Q000188:drug therapy; D011085:Polycystic Ovary Syndrome / Q000188:drug therapy; D051880:Receptors, Notch / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology*; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
chemical_list: D048868:Adaptor Proteins, Signal Transducing; D000634:Aminoquinolines; D002135:Calcium-Binding Proteins; D006063:Chorionic Gonadotropin; C424126:DLL4 protein, human; D036341:Intercellular Signaling Peptides and Proteins; D051880:Receptors, Notch; D042461:Vascular Endothelial Growth Factor A; C046650:quinagolide; D007986:Luteinizing Hormone; D015232:Dinoprostone